...

24.01.2020

Global Womens HealthCare Market Expected to be More than $17.8 billion, at CAGR of Nearly 13.2% by 2024: MarketsAndMarkets

North America commanded the largest share of the Women’s Health Care Market in 2019.
According to the new market research report "Women''s HealthCare Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024 ", published by MarketsandMarkets

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136585329

The Women''s Health Care Market growth is largely driven by the growing incidence of chronic health conditions among women, government initiatives to curb population growth, growing demand for contraceptives to prevent unintended pregnancies, and the growing focus on R&D by key players for the development of advanced products. On the other hand, the reluctance to use contraceptives is a major factor limiting the Women''s HealthCare Market growth.

Prolia is the largest and fastest-growing segment of the market.

Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. Prolia has shown a considerable year-on-year growth primarily due to increasing unit demand. Prolia has witnessed positive market growth owing to the increasing prevalence of postmenopausal osteoporosis in the US.

Browse and in-depth TOC on "Women"
127 - Tables
27 - Figures
146 - Pages

The postmenopausal osteoporosis segment is expected to grow at the highest CAGR during the forecast period.

On the basis of application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment is expected to grow at a higher CAGR during the forecast period. The growing prevalence of postmenopausal osteoporosis and a high risk of osteoporosis fractures are the prime factors that contribute towards the large share of this segment. Furthermore, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis also supports the growth of this segment. The postmenopausal osteoporosis segment also holds the largest share of the market owing to these factors.



Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=136585329

In 2018, North America was the largest and the fastest-growing regional market for womenen, easy access to modern contraception as compared to developing countries, and increased healthcare spending also support the growth of this market.

The prominent players in the global Women& Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US).






Firma: marketsandmarkets

Kontakt-Informationen:
Ansprechpartner: shelly singh
Stadt: northbook
Telefon: 18886006441


Diese PresseMitteilung kommt von businesspress24.com
http://m.businesspress24.com

Die URL für diese PresseMitteilung ist:
http://m.businesspress24.com/pressrelease1555449.html


Die PresseMitteilung stellt eine Meinungsäußerung des Erfassers dar. Der Erfasser hat versichert, dass die eingestellte PresseMitteilung der Wahrheit entspricht, dass sie frei von Rechten Dritter ist und zur Veröffentlichung bereitsteht. businesspress24.com macht sich die Inhalte der PresseMitteilungen nicht zu eigen. Die Haftung für eventuelle Folgen (z.B. Abmahnungen, Schadenersatzforderungen etc.) übernimmt der Eintrager und nicht businesspress24.com